CEO Renee Gala was paid $19,151,558 in fiscal year 2025, ↑ up 188.9% from fiscal year 2024, the 46th percentile of its disclosed peer group (SEC filing 0001232524-26-000029 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$19,151,558 ↑ Renee Gala total, FY2025 | 46th CEO pay percentile vs peers | 69:1 CEO-to-median pay ratio | 93.8% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
JAZZ's next annual pay disclosure, estimated June 10, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Renee Gala | $1,003,269 | $0 | $16,138,433 | $0 | $1,980,000 | $0 | $29,856 | $19,151,558 |
| President, CEO and Director | ||||||||
| Bruce Cozadd | 884,789 | 971,094 | 4,855,123 | 12,041,389 | 0 | 0 | 82,441 | 18,834,836 |
| Chairperson and Former CEO | ||||||||
| Robert Iannone | 793,077 | 0 | 6,953,879 | 0 | 840,000 | 0 | 24,802 | 8,661,758 |
| Executive Vice President, Global Head of Research and Development and Chief Medical Officer | ||||||||
| Philip Johnson | 741,346 | 0 | 6,046,903 | 0 | 730,000 | 0 | 26,224 | 7,544,473 |
| Executive Vice President and CFO | ||||||||
| Neena Patil | 715,481 | 0 | 4,844,096 | 0 | 720,000 | 0 | 19,962 | 6,299,539 |
| Executive Vice President and Chief Legal Officer | ||||||||
| Samantha Pearce | 695,673 | 0 | 4,659,014 | 0 | 690,000 | 0 | 31,440 | 6,076,127 |
| Executive Vice President, Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Renee Gala | $19,151,558 | $6,628,888 | $5,434,388 | ↑ +12,522,670 |
| Bruce Cozadd | 18,834,836 | 15,527,464 | 15,341,235 | ↑ +3,307,372 |
| Robert Iannone | 8,661,758 | 5,689,377 | 4,979,077 | ↑ +2,972,381 |
| Philip Johnson | 7,544,473 | 5,243,445 | — | ↑ +2,301,028 |
| Neena Patil | 6,299,539 | 4,309,074 | 3,877,435 | ↑ +1,990,465 |
| Samantha Pearce | 6,076,127 | 4,464,254 | — | ↑ +1,611,873 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Jazz Pharmaceuticals plc's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper JAZZ reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Jazz Pharmaceuticals plc Peer Teardown Report
$19,151,558 Renee Gala total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 7, 2026 · Source: 0001232524-26-000029 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for JAZZ
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order JAZZ
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name JAZZ as a peer is temporarily unavailable — recheck shortly.
Get the Jazz Pharmaceuticals plc Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Anne O'Riordan | Independent Director | $495,564 |
| Heather Ann McSharry | Independent Director | $528,064 |
| Jennifer E. Cook | Independent Director | $520,564 |
| Kenneth W. O'Keefe | Former director (through FY2025) | $475,910 |
| Laura J. Hamill | Independent Director | $480,564 |
| Mark D. Smith | Independent Director | $490,564 |
| Norbert G. Riedel | Independent Director | $518,064 |
| Patrick G. Enright | Independent Director | $495,564 |
| Patrick Kennedy | Independent Director | $503,064 |
| Rick E Winningham | Lead Independent Director | $555,564 |
| Seamus C. Mulligan | Independent Director | $500,564 |
| Ted W. Love | Independent Director | $8,542 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Neena Patil | EVP & Chief Legal Officer | 2026-06-10 | D | 1,200 | $232 | $278,196 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-06-15 | D | 1,157 | 231 | 266,746 | Common | Form 4 ↗ |
| Philip Johnson | EVP & Chief Financial Officer | 2026-06-30 | D | 3,343 | 238 | 794,698 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-06-30 | D | 3,764 | 238 | 894,778 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-06-30 | D | 4,835 | 238 | 1,149,376 | Common | Form 4 ↗ |
| Samantha Pearce | EVP, Chief Commercial Officer | 2026-06-30 | D | 2,527 | 238 | 600,718 | Common | Form 4 ↗ |
| Neena Patil | EVP & Chief Legal Officer | 2026-06-30 | D | 2,678 | 238 | 636,614 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-07-01 | D | 6,000 | 240 | 1,442,820 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-03 | D | 6,000 | 253 | 1,517,880 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Seamus C. Mulligan | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Samantha Pearce | EVP, Chief Commercial Officer | 2026-08-05 | D | 780 | 262 | 204,064 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 27,584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 2,916 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 300 | 253 | 75,828 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 18,187 | 248 | 4,507,781 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 884 | 113 | 99,980 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 26,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-27 | — | 884 | — | — | 1 insider, 1 accrual row | ||
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 9,259 | 252 | 2,332,804 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 19,639 | 251 | 4,921,596 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 18,113 | 250 | 4,528,572 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 11,423 | 249 | 2,840,516 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 2,916 | 137 | 399,842 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 27,584 | 137 | 3,782,318 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 26,116 | 113 | 2,953,720 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-31 | D | 15 | 244 | 3,661 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-31 | D | 1,840 | 241 | 444,158 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-08-31 | D | 2,076 | 241 | 501,126 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-31 | D | 15 | 245 | 3,670 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-31 | D | 1,840 | 241 | 444,158 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-31 | D | 14 | 244 | 3,417 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-31 | D | 1,209 | 241 | 291,840 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-31 | D | 10 | 244 | 2,441 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-31 | D | 737 | 241 | 177,904 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-31 | D | 6 | 244 | 1,464 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-08-31 | D | 16 | 245 | 3,914 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-31 | D | 14 | 244 | 3,417 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-09-01 | D | 6,000 | 250 | 1,500,780 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-09-08 | D | 15 | 241 | 3,618 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-09-08 | D | 1,412 | 243 | 343,158 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-09-08 | D | 2,000 | 243 | 486,060 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-09-08 | D | 1,967 | 247 | 485,475 | Common | Form 4 ↗ |
| Neena Patil | EVP & Chief Legal Officer | 2026-09-10 | D | 1,200 | 241 | 289,128 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-10-01 | D | 6,000 | 230 | 1,381,980 | Common | Form 4 ↗ |
| Renee D. Gala | Director | 2026-10-06 | D | 2,000 | 236 | 472,800 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Neena Patil | EVP & Chief Legal Officer | 2026-06-10 | D | 1,200 | $232 | $278,196 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-06-15 | D | 1,157 | 231 | 266,746 | Common | Form 4 ↗ |
| Philip Johnson | EVP & Chief Financial Officer | 2026-06-30 | D | 3,343 | 238 | 794,698 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-06-30 | D | 3,764 | 238 | 894,778 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-06-30 | D | 4,835 | 238 | 1,149,376 | Common | Form 4 ↗ |
| Samantha Pearce | EVP, Chief Commercial Officer | 2026-06-30 | D | 2,527 | 238 | 600,718 | Common | Form 4 ↗ |
| Neena Patil | EVP & Chief Legal Officer | 2026-06-30 | D | 2,678 | 238 | 636,614 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-07-01 | D | 6,000 | 240 | 1,442,820 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-03 | D | 6,000 | 253 | 1,517,880 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Seamus C. Mulligan | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Samantha Pearce | EVP, Chief Commercial Officer | 2026-08-05 | D | 780 | 262 | 204,064 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-05 | A | 1,605 | 0 | 0 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 27,584 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 2,916 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 300 | 253 | 75,828 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 18,187 | 248 | 4,507,781 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 884 | 113 | 99,980 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 26,116 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 884 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 9,259 | 252 | 2,332,804 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 19,639 | 251 | 4,921,596 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 18,113 | 250 | 4,528,572 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | D | 11,423 | 249 | 2,840,516 | Common, open-market sale | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 2,916 | 137 | 399,842 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 27,584 | 137 | 3,782,318 | Common | Form 4 ↗ |
| Robert Iannone | EVP, Global Head of R&D & CMO | 2026-08-27 | A | 26,116 | 113 | 2,953,720 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-31 | D | 15 | 244 | 3,661 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-31 | D | 1,840 | 241 | 444,158 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-08-31 | D | 2,076 | 241 | 501,126 | Common | Form 4 ↗ |
| Heather Ann McSharry | Director | 2026-08-31 | D | 15 | 245 | 3,670 | Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Patrick Kennedy | Director | 2026-08-31 | D | 1,840 | 241 | 444,158 | Common | Form 4 ↗ |
| Jennifer E. Cook | Director | 2026-08-31 | D | 14 | 244 | 3,417 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-31 | D | 1,209 | 241 | 291,840 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-08-31 | D | 10 | 244 | 2,441 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Rick E Winningham | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-31 | D | 737 | 241 | 177,904 | Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-08-31 | D | 6 | 244 | 1,464 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Norbert G. Riedel | Director | 2026-08-31 | D | 14 | 245 | 3,425 | Common | Form 4 ↗ |
| Mark D. Smith | Director | 2026-08-31 | D | 1,692 | 241 | 408,432 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-08-31 | D | 16 | 245 | 3,914 | Common | Form 4 ↗ |
| Laura J. Hamill | Director | 2026-08-31 | D | 14 | 244 | 3,417 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-09-01 | D | 6,000 | 250 | 1,500,780 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-09-08 | D | 15 | 241 | 3,618 | Common | Form 4 ↗ |
| Mary Elizabeth Henderson | SVP, Technical Operations | 2026-09-08 | D | 1,412 | 243 | 343,158 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-09-08 | D | 2,000 | 243 | 486,060 | Common | Form 4 ↗ |
| Renee D. Gala | President & CEO | 2026-09-08 | D | 1,967 | 247 | 485,475 | Common | Form 4 ↗ |
| Neena Patil | EVP & Chief Legal Officer | 2026-09-10 | D | 1,200 | 241 | 289,128 | Common | Form 4 ↗ |
| Bruce C. Cozadd | Director | 2026-10-01 | D | 6,000 | 230 | 1,381,980 | Common | Form 4 ↗ |
| Renee D. Gala | Director | 2026-10-06 | D | 2,000 | 236 | 472,800 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Neena Patil | PSU | 2025-02-27 | 2,065 | 12,518 | — | 25,036 | $2,222,830 |
| Robert Iannone | PSU | 2025-02-27 | 2,923 | 17,718 | — | 35,436 | 3,146,195 |
| Renee Gala | RSU | 2025-02-27 | — | — | 23,111 | — | 3,311,111 |
| Renee Gala | RSU | 2025-02-27 | — | — | 11,555 | — | 1,655,484 |
| Renee Gala | RSU | 2025-08-07 | — | — | 18,808 | — | 2,107,999 |
| Philip Johnson | RSU | 2025-02-27 | — | — | 15,407 | — | 2,207,359 |
| Samantha Pearce | PSU | 2025-02-27 | 1,970 | 11,941 | — | 23,882 | 2,120,415 |
| Philip Johnson | RSU | 2025-02-27 | — | — | 7,704 | — | 1,103,751 |
| Robert Iannone | RSU | 2025-02-27 | — | — | 17,718 | — | 2,538,456 |
| Bruce Cozadd | RSU | 2025-11-20 | — | — | 2,506 | — | 440,404 |
| Samantha Pearce | RSU | 2025-02-27 | — | — | 5,778 | — | 827,813 |
| Samantha Pearce | RSU | 2025-02-27 | — | — | 11,941 | — | 1,710,786 |
| Renee Gala | PSU | 2025-08-07 | 12,792 | 38,185 | — | 76,370 | 4,959,977 |
| Philip Johnson | PSU | 2025-02-27 | 2,542 | 15,407 | — | 30,814 | 2,735,792 |
| Neena Patil | RSU | 2025-02-27 | — | — | 5,778 | — | 827,813 |
| Bruce Cozadd | RSU | 2025-02-27 | — | — | 30,814 | — | 4,414,719 |
| Renee Gala | PSU | 2025-02-27 | 3,813 | 23,111 | — | 46,222 | 4,103,863 |
| Neena Patil | RSU | 2025-02-27 | — | — | 12,518 | — | 1,793,453 |
| Robert Iannone | RSU | 2025-02-27 | — | — | 8,859 | — | 1,269,228 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Neena Patil | $2,621,266 | $2,222,830 | $0 | 45.9% |
| Robert Iannone | 3,807,684 | 3,146,195 | 0 | 45.2% |
| Renee Gala | 7,074,594 | 9,063,840 | 0 | 56.2% |
| Philip Johnson | 3,311,110 | 2,735,792 | 0 | 45.2% |
| Samantha Pearce | 2,538,599 | 2,120,415 | 0 | 45.5% |
| Bruce Cozadd | 4,855,123 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Neena Patil | RSU | 25,036 | — | $4,256,120 |
| Neena Patil | RSU | 5,778 | — | 982,260 |
| Renee Gala | PSU | 46,222 | — | 7,857,740 |
| Bruce Cozadd | RSU | 35,924 | — | 6,107,080 |
| Philip Johnson | PSU | 31,864 | — | 5,416,880 |
| Samantha Pearce | PSU | 24,122 | — | 4,100,740 |
| Samantha Pearce | PSU | 23,882 | — | 4,059,940 |
| Bruce Cozadd | RSU | 20,228 | — | 3,438,760 |
| Robert Iannone | RSU | 11,699 | — | 1,988,830 |
| Neena Patil | RSU | 8,852 | — | 1,504,840 |
| Renee Gala | RSU | 11,555 | — | 1,964,350 |
| Samantha Pearce | RSU | 3,798 | — | 645,660 |
| Renee Gala | RSU | 386 | — | 65,620 |
| Renee Gala | RSU | 6,392 | — | 1,086,640 |
| Samantha Pearce | RSU | 959 | — | 163,030 |
| Neena Patil | RSU | 2,221 | — | 377,570 |
| Renee Gala | RSU | 18,808 | — | 3,197,360 |
| Renee Gala | PSU | 39,832 | — | 6,771,440 |
| Robert Iannone | RSU | 8,859 | — | 1,506,030 |
| Bruce Cozadd | RSU | 10,686 | — | 1,816,620 |
| Samantha Pearce | RSU | 1,934 | — | 328,780 |
| Robert Iannone | RSU | 6,223 | — | 1,057,910 |
| Philip Johnson | RSU | 11,949 | — | 2,031,330 |
| Robert Iannone | RSU | 2,843 | — | 483,310 |
| Renee Gala | RSU | 23,111 | — | 3,928,870 |
| Robert Iannone | PSU | 17,718 | — | 3,012,060 |
| Philip Johnson | RSU | 15,407 | — | 2,619,190 |
| Neena Patil | RSU | 4,709 | — | 800,530 |
| Samantha Pearce | RSU | 5,778 | — | 982,260 |
| Robert Iannone | RSU | 12,696 | — | 2,158,320 |
| Renee Gala | RSU | 14,937 | — | 2,539,290 |
| Samantha Pearce | RSU | 11,941 | — | 2,029,970 |
| Samantha Pearce | RSU | 5,247 | — | 891,990 |
| Bruce Cozadd | RSU | 57,012 | — | 9,692,040 |
| Philip Johnson | RSU | 7,704 | — | 1,309,680 |
| Robert Iannone | PSU | 33,856 | — | 5,755,520 |
| Bruce Cozadd | RSU | 35,917 | — | 6,105,890 |
| Bruce Cozadd | PSU | 2,506 | — | 426,020 |
| Renee Gala | PSU | 76,370 | — | 12,982,900 |
| Robert Iannone | RSU | 35,436 | — | 6,024,120 |
| Philip Johnson | PSU | 30,814 | — | 5,238,380 |
| Neena Patil | PSU | 24,696 | — | 4,198,320 |
| Renee Gala | RSU | 12,741 | — | 2,165,970 |
| Neena Patil | PSU | 12,518 | — | 2,128,060 |
| Neena Patil | RSU | 9,261 | — | 1,574,370 |
| Samantha Pearce | RSU | 3,637 | — | 618,290 |
| Renee Gala | RSU | 2,932 | — | 498,440 |
Our executive compensation program is designed to support the following philosophy and objectives: Attract, incentivize, reward and retain experienced, talented individuals with relevant experience in the life sciences industry through a competitive pay structure... Deliver balanced total compensation packages to accomplish our business objectives and mission... Align pay with our performance
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-07-23 | 50,608,405 | 3,345,782 | 45,600 | 93.8% | Passed |
| 2025 | 2025-07-24 | 48,261,149 | 2,887,574 | 193,593 | 94.35% | Passed |
| 2024 | 2024-07-25 | 49,319,464 | 4,780,265 | 241,082 | 91.16% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-07-23 | 93.8%a |
| 2025 | 2025-07-24 | 94.35%b |
| 2024 | 2024-07-25 | 91.16%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Our board recommends a vote "FOR" this proposal. Vote required for approval: Affirmative vote of a majority of the votes cast on the proposal. For more information, see Proposal 3 starting on page 95 .”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 69 : 1 |
|---|---|
| CEO total compensation | $19,151,558 |
| Median employee compensation | $281,424 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Rick E WinninghamIndependent · Lead Independent Director · Compensation Committee · Nominating Committee · SMC | $162,500 | $393,064 | $0 | $0 | $0 | $555,564 |
| Heather Ann McSharryIndependent · Nominating Committee (Chair) · Audit Committee · Transaction Committee | 135,000 | 393,064 | 0 | 0 | 0 | 528,064 |
| Jennifer E. CookIndependent · Compensation Committee (Chair) · SMC | 127,500 | 393,064 | 0 | 0 | 0 | 520,564 |
| Norbert G. RiedelIndependent · SMC (Chair) · Nominating Committee | 125,000 | 393,064 | 0 | 0 | 0 | 518,064 |
| Patrick KennedyIndependent · Audit Committee (Chair) · Transaction Committee | 110,000 | 393,064 | 0 | 0 | 0 | 503,064 |
| Seamus C. MulliganIndependent · SMC · Transaction Committee (Chair) | 107,500 | 393,064 | 0 | 0 | 0 | 500,564 |
| Patrick G. EnrightIndependent · Audit Committee · Compensation Committee | 102,500 | 393,064 | 0 | 0 | 0 | 495,564 |
| Anne O'RiordanIndependent · Not standing for re-election | 102,500 | 393,064 | 0 | 0 | 0 | 495,564 |
| Mark D. SmithIndependent · SMC | 97,500 | 393,064 | 0 | 0 | 0 | 490,564 |
| Laura J. HamillIndependent · Compensation Committee | 87,500 | 393,064 | 0 | 0 | 0 | 480,564 |
| Kenneth W. O'KeefeIndependent · Audit Committee · Departed during FY | 82,846 | 393,064 | 0 | 0 | 0 | 475,910 |
| Ted W. LoveIndependent · Audit Committee · Partial-year service · Newly elected | 8,542 | 0 | 0 | 0 | 0 | 8,542 |
| Renee D. GalaEmployee director · Partial-year service | 0 | 0 | 0 | — | 0 | 0 |
| Bruce C. CozaddIndependent · Board Chair | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 / 20,000 |
| Stock ownership guideline | each of our other continuing NEOs has five years from the date of his or her appointment to comply with the guidelines. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,248,888 |
| Equity awards (grant-date value) | $4,323,704 |
| All other compensation | $0 |
| Total cost of the board | $5,572,592 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Jazz Pharmaceuticals plc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Jazz Pharmaceuticals plc.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 4 | Biogen, Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 5 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 6 | Vertex Pharmaceuticals Incorporated | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 7 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 8 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 9 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 10 | Organon & Co. | 2025 | Kevin Ali | 1,088,462 | 10,251,989 | 3,249,999 | 0 | 15,813,296 |
| 11 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 12 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 13 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 14 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Biogen, Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Gilead Sciences, Inc. | 180% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Organon & Co. | 72% | PSU 50 · RSU 25 · Options 25 | Yes — Three-Year Relative TSR | Korn Ferry |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vertex Pharmaceuticals Incorporated | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Renee Gala | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 2 | Section 01, Bruce Cozadd | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 18,834,836. Filing ↗machine: r8 · c27 · span 1449195–1449205 |
| 3 | Section 01, Robert Iannone | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 8,661,758. Filing ↗machine: t235 · r11 · c9 · span 1456132–1456141 |
| 4 | Section 01, Philip Johnson | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 7,544,473. Filing ↗machine: r6 · c27 · span 1444247–1444256 |
| 5 | Section 01, Neena Patil | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 6,299,539. Filing ↗machine: r14 · c27 · span 1463121–1463130 |
| 6 | Section 01, Samantha Pearce | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Summary Compensation Table”. As printed: 6,076,127. Filing ↗machine: r17 · c27 · span 1470190–1470199 |
| 7 | Section 03, Neena Patil PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r26 · c12 · span 1738700–1738706 |
| 8 | Section 03, Robert Iannone PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r20 · c12 · span 1713058–1713064 |
| 9 | Section 03, Renee Gala RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r5 · c11 · span 1651384–1651390 |
| 10 | Section 03, Renee Gala RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r6 · c11 · span 1655557–1655563 |
| 11 | Section 03, Renee Gala RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r4 · c12 · span 1647512–1647518 |
| 12 | Section 03, Philip Johnson RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r12 · c12 · span 1679320–1679326 |
| 13 | Section 03, Samantha Pearce PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r32 · c12 · span 1764180–1764186 |
| 14 | Section 03, Philip Johnson RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r13 · c10 · span 1683668–1683673 |
| 15 | Section 03, Robert Iannone RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r20 · c12 · span 1713058–1713064 |
| 16 | Section 03, Bruce Cozadd RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r15 · c12 · span 1692390–1692395 |
| 17 | Section 03, Samantha Pearce RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r33 · c10 · span 1768053–1768058 |
| 18 | Section 03, Samantha Pearce RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r32 · c12 · span 1764180–1764186 |
| 19 | Section 03, Renee Gala PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r4 · c18 · span 1648574–1648580 |
| 20 | Section 03, Philip Johnson PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r12 · c12 · span 1679320–1679326 |
| 21 | Section 03, Neena Patil RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r27 · c11 · span 1743086–1743091 |
| 22 | Section 03, Bruce Cozadd RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗ |
| 23 | Section 03, Renee Gala PSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r5 · c11 · span 1651384–1651390 |
| 24 | Section 03, Neena Patil RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r26 · c12 · span 1738700–1738706 |
| 25 | Section 03, Robert Iannone RSU | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Grants of Plan-Based Awards in Fiscal 202” · grants of plan-based awards table. Filing ↗machine: t251 · r21 · c11 · span 1717444–1717449 |
| 26 | Section 07, pay ratio | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “CEO Pay Ratio”. As printed: 69 : 1. Filing ↗machine: span 1944627–1944634 |
| 27 | Section 08, Rick E Winningham | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 555,564. Filing ↗machine: t80 · r14 · c6 · span 629658–629933 |
| 28 | Section 08, Heather Ann McSharry | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 528,064. Filing ↗machine: t80 · r8 · c6 · span 620507–620750 |
| 29 | Section 08, Jennifer E. Cook | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 520,564. Filing ↗machine: t80 · r3 · c6 · span 613115–613326 |
| 30 | Section 08, Norbert G. Riedel | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 518,064. Filing ↗machine: t80 · r12 · c6 · span 626549–626792 |
| 31 | Section 08, Patrick Kennedy | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 503,064. Filing ↗machine: t80 · r6 · c6 · span 617411–617654 |
| 32 | Section 08, Seamus C. Mulligan | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 500,564. Filing ↗machine: t80 · r9 · c6 · span 621977–622220 |
| 33 | Section 08, Patrick G. Enright | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 495,564. Filing ↗machine: t80 · r4 · c6 · span 614478–614721 |
| 34 | Section 08, Anne O'Riordan | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 495,564. Filing ↗machine: t80 · r11 · c6 · span 625084–625327 |
| 35 | Section 08, Mark D. Smith | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 490,564. Filing ↗machine: t80 · r13 · c6 · span 628008–628251 |
| 36 | Section 08, Laura J. Hamill | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 480,564. Filing ↗machine: t80 · r5 · c6 · span 615944–616187 |
| 37 | Section 08, Kenneth W. O'Keefe | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 475,910. Filing ↗machine: t80 · r10 · c6 · span 623623–623866 |
| 38 | Section 08, Ted W. Love | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 8,542. Filing ↗machine: t80 · r7 · c2 · span 618459–618583 |
| 39 | Section 08, Renee D. Gala | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 40 | Section 08, Bruce C. Cozadd | DEF 14A | 2026-06-08 | 0001232524-26-000029 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 41 | Section 02, Neena Patil 2026-06-10 | Form 4 | 2026-06-12 | 0001783908-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Mark D. Smith 2026-06-15 | Form 4 | 2026-06-17 | 0001756253-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Philip Johnson 2026-06-30 | Form 4 | 2026-07-02 | 0002013156-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Robert Iannone 2026-06-30 | Form 4 | 2026-07-02 | 0001737329-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Renee D. Gala 2026-06-30 | Form 4 | 2026-07-02 | 0001607737-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Samantha Pearce 2026-06-30 | Form 4 | 2026-07-02 | 0001805688-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Neena Patil 2026-06-30 | Form 4 | 2026-07-02 | 0001783908-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Bruce C. Cozadd 2026-07-01 | Form 4 | 2026-07-06 | 0001193210-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Bruce C. Cozadd 2026-08-03 | Form 4 | 2026-08-05 | 0001193210-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Bruce C. Cozadd 2026-08-05 | Form 4 | 2026-08-07 | 0001193210-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Norbert G. Riedel 2026-08-05 | Form 4 | 2026-08-07 | 0001161662-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Seamus C. Mulligan 2026-08-05 | Form 4 | 2026-08-07 | 0001536639-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Jennifer E. Cook 2026-08-05 | Form 4 | 2026-08-07 | 0001754371-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Mark D. Smith 2026-08-05 | Form 4 | 2026-08-07 | 0001756253-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Patrick Kennedy 2026-08-05 | Form 4 | 2026-08-07 | 0002013944-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Laura J. Hamill 2026-08-05 | Form 4 | 2026-08-07 | 0001751804-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Patrick G. Enright 2026-08-05 | Form 4 | 2026-08-07 | 0001253886-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Heather Ann McSharry 2026-08-05 | Form 4 | 2026-08-07 | 0001576068-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Ted W. Love 2026-08-05 | Form 4 | 2026-08-07 | 0001188919-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Samantha Pearce 2026-08-05 | Form 4 | 2026-08-07 | 0001805688-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Rick E Winningham 2026-08-05 | Form 4 | 2026-08-07 | 0001302443-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Robert Iannone 2026-08-27 | Form 4 | 2026-08-31 | 0001737329-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Patrick Kennedy 2026-08-31 | Form 4 | 2026-09-02 | 0002013944-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Heather Ann McSharry 2026-08-31 | Form 4 | 2026-09-02 | 0001576068-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Patrick G. Enright 2026-08-31 | Form 4 | 2026-09-02 | 0001253886-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Jennifer E. Cook 2026-08-31 | Form 4 | 2026-09-02 | 0001754371-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Mark D. Smith 2026-08-31 | Form 4 | 2026-09-02 | 0001756253-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Mary Elizabeth Henderson 2026-08-31 | Form 4 | 2026-09-02 | 0001989533-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Heather Ann McSharry 2026-08-31 | Form 4 | 2026-09-02 | 0001576068-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Patrick G. Enright 2026-08-31 | Form 4 | 2026-09-02 | 0001253886-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Patrick Kennedy 2026-08-31 | Form 4 | 2026-09-02 | 0002013944-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jennifer E. Cook 2026-08-31 | Form 4 | 2026-09-02 | 0001754371-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Bruce C. Cozadd 2026-08-31 | Form 4 | 2026-09-02 | 0001193210-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Bruce C. Cozadd 2026-08-31 | Form 4 | 2026-09-02 | 0001193210-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Rick E Winningham 2026-08-31 | Form 4 | 2026-09-02 | 0001302443-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Rick E Winningham 2026-08-31 | Form 4 | 2026-09-02 | 0001302443-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Laura J. Hamill 2026-08-31 | Form 4 | 2026-09-02 | 0001751804-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Ted W. Love 2026-08-31 | Form 4 | 2026-09-02 | 0001188919-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Ted W. Love 2026-08-31 | Form 4 | 2026-09-02 | 0001188919-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Norbert G. Riedel 2026-08-31 | Form 4 | 2026-09-02 | 0001161662-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Norbert G. Riedel 2026-08-31 | Form 4 | 2026-09-02 | 0001161662-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Mark D. Smith 2026-08-31 | Form 4 | 2026-09-02 | 0001756253-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Mary Elizabeth Henderson 2026-08-31 | Form 4 | 2026-09-02 | 0001989533-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Laura J. Hamill 2026-08-31 | Form 4 | 2026-09-02 | 0001751804-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Bruce C. Cozadd 2026-09-01 | Form 4 | 2026-09-02 | 0001193210-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Mary Elizabeth Henderson 2026-09-08 | Form 4 | 2026-09-10 | 0001989533-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Mary Elizabeth Henderson 2026-09-08 | Form 4 | 2026-09-10 | 0001989533-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Renee D. Gala 2026-09-08 | Form 4 | 2026-09-10 | 0001607737-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Renee D. Gala 2026-09-08 | Form 4 | 2026-09-10 | 0001607737-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Neena Patil 2026-09-10 | Form 4 | 2026-09-14 | 0001783908-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Bruce C. Cozadd 2026-10-01 | Form 4 | 2026-10-05 | 0001193210-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Renee D. Gala 2026-10-06 | Form 4 | 2026-10-07 | 0001607737-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 06, 2026 vote | Form 8-K | 2026-07-24 | 0001628280-26-049466 | Item 5.07 · say-on-pay result. As reported: 93.8% (votes for as printed: 50,608,405). Filing ↗ |
| 107 | Section 06, 2025 vote | Form 8-K | 2025-07-25 | 0001232524-25-000051 | Item 5.07 · say-on-pay result. As reported: 94.35% (votes for as printed: 48,261,149). Filing ↗ |
| 108 | Section 06, 2024 vote | Form 8-K | 2024-07-26 | 0001232524-24-000056 | Item 5.07 · say-on-pay result. As reported: 91.16% (votes for as printed: 49,319,464). Filing ↗ |
| 109 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 110 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 111 | Section 09b board cost (computed) | Computed | — | — | Cash 1,248,888 + equity 4,323,704 + all other 0 = 5,572,592, summed across the director compensation table rows.machine: formula: Σ = 5,572,592 |
| 112 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 113 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 114 | Gilead Sciences, Inc., Section 10b CEO total | DEF 14A | 2026-03-20 | 0001308179-26-000106 | CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. Filing ↗machine: t414 · r1 · c29 · span 989582–989592 |
| 115 | Biogen, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen, Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 116 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 117 | Vertex Pharmaceuticals Incorporated, Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 118 | Moderna, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001308179-26-000081 | CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898 |
| 119 | Jazz Pharmaceuticals plc (subject), Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 120 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 121 | Organon & Co., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177411 | CEO total compensation as printed in Organon & Co.'s own proxy. As printed: 15,813,296. Filing ↗machine: r30 · c18 · span 3922588–3922598 |
| 122 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 123 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 124 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 125 | Regeneron Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001308179-26-000340 | CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. Filing ↗machine: r3 · c10 · span 3335980–3335989 |
| 126 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 127 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc. names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 128 | Section 10a, Regeneron Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001308179-26-000340 | Regeneron Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Jazz Pharmaceuticals plc. Filing ↗ |
| 129 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc. names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 130 | Section 10a, Gilead Sciences, Inc. reciprocity | DEF 14A | — | 0001308179-26-000106 | Gilead Sciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Jazz Pharmaceuticals plc. Filing ↗ |
| 131 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 132 | Section 10a, Vertex Pharmaceuticals Incorporated reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals Incorporated names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 133 | Section 10a, Moderna, Inc. reciprocity | DEF 14A | — | 0001308179-26-000081 | Moderna, Inc. names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 134 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Jazz Pharmaceuticals plc. Filing ↗ |
| 135 | Section 10a, Organon & Co. reciprocity | DEF 14A | — | 0001193125-26-177411 | Organon & Co. names Jazz Pharmaceuticals plc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Jazz Pharmaceuticals plc Executive Compensation Report
$1,500